Biodegradable Stent Market Size, Growth and Forecast 2032

Market Overview

The Biodegradable Stent Market is projected to grow from USD 298.71 million in 2023 to an estimated USD 572.70 million by 2032, exhibiting a compound annual growth rate (CAGR) of 7.50% from 2024 to 2032. This growth is driven by increasing demand for minimally invasive procedures, rising prevalence of cardiovascular diseases, and a growing preference for bioresorbable materials in stent technology.

Key drivers of the biodegradable stent market include the rising geriatric population, a shift towards bioresorbable stent materials, and increased awareness of non-invasive treatment options. Moreover, ongoing research and development efforts by leading healthcare companies are expected to further drive market growth by improving stent design, safety, and performance.

Geographically, North America holds the largest share of the biodegradable stent market, attributed to the high incidence of cardiovascular diseases and advanced healthcare infrastructure. Europe follows closely, driven by a strong focus on medical research and development. Key players in the market include Abbott Laboratories, Boston Scientific Corporation, Elixir Medical Corporation, and Meril Life Sciences, who are continuously innovating to capture a larger market share.

Market Drivers

Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases (CVDs) remain the leading cause of death globally, with millions of people affected by conditions such as coronary artery disease (CAD), stroke, and heart failure. According to the World Health Organization (WHO), CVDs account for a significant portion of global deaths annually. The growing prevalence of these diseases has significantly increased the demand for effective treatment options, including stenting procedures, which are widely used to open blocked arteries and restore blood flow to the heart.

Biodegradable stents offer a promising alternative to conventional metallic stents, as they dissolve within the body after fulfilling their function, reducing the risks of long-term complications such as restenosis (re-narrowing of arteries) and thrombosis (blood clot formation). The rising awareness of these benefits is leading to a greater preference for biodegradable stents among healthcare providers and patients. Moreover, as healthcare systems across the world grapple with the increasing burden of CVDs, the demand for advanced and safer treatment options like biodegradable stents is expected to rise, further driving market growth. For instance, recent surveys by the American Heart Association highlight the urgent need for innovative treatments to combat the global burden of cardiovascular diseases.

Technological Advancements in Stent Design and Materials

The global biodegradable stent market is benefiting significantly from rapid advancements in stent design and the development of bioresorbable materials. Traditional stents, often made of metal alloys, are permanent implants that remain in the body even after they are no longer required. This can lead to long-term complications such as chronic inflammation, thrombosis, and the need for additional surgical interventions. In contrast, biodegradable stents are designed to gradually dissolve within the body once they have served their purpose, reducing the need for subsequent treatments.The evolution of bioresorbable materials, such as polylactic acid (PLA) and magnesium-based alloys, has been a game-changer in the development of biodegradable stents. These materials not only provide the necessary mechanical support during the critical healing period but also dissolve safely, eliminating the risks associated with permanent implants. Furthermore, advancements in coating technologies, such as drug-eluting biodegradable stents, have improved the efficacy of stenting procedures by releasing anti-inflammatory or anti-proliferative drugs to prevent restenosis. As a result, the ongoing innovation in materials and stent design is a significant driver of market growth, encouraging healthcare professionals to adopt biodegradable stents over traditional alternatives. For instance, recent advancements in drug-eluting stents have shown promising results in reducing cardiovascular events.

Minimally invasive procedures have gained significant traction in modern healthcare due to their numerous advantages, including reduced recovery times, lower risks of infection, and shorter hospital stays. This trend is particularly evident in the treatment of cardiovascular diseases, where patients are increasingly opting for less invasive options such as percutaneous coronary interventions (PCI) over more invasive surgical procedures like coronary artery bypass grafting (CABG). Biodegradable stents align well with this growing preference for minimally invasive interventions. Unlike traditional stents, which remain as permanent fixtures in the body, biodegradable stents provide temporary support and then safely dissolve, reducing the need for long-term follow-up treatments or invasive removal procedures. This feature is particularly appealing to both patients and physicians, as it minimizes the risks associated with permanent implants while offering effective treatment for blocked arteries. The increasing popularity of minimally invasive treatments, along with the expanding geriatric population, is expected to boost the demand for biodegradable stents in the coming years. For instance, recent studies have shown the durability and effectiveness of minimally invasive procedures in treating various conditions.

Government and Regulatory Support for Advanced Stenting Solutions

The global healthcare landscape is witnessing growing support from government bodies and regulatory agencies for the adoption of advanced medical technologies, including biodegradable stents. Governments in several countries are investing in healthcare infrastructure and promoting the use of innovative medical devices that improve patient outcomes while reducing healthcare costs. This has led to favorable reimbursement policies and regulatory approvals for biodegradable stents, further encouraging their adoption in clinical settings. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have been instrumental in approving the use of biodegradable stents, recognizing their potential to reduce long-term complications associated with traditional stents. For instance, the approval of bioresorbable vascular scaffolds (BVS), a type of biodegradable stent, has paved the way for wider acceptance of biodegradable stents in clinical practice. Furthermore, government initiatives aimed at reducing the burden of cardiovascular diseases through early diagnosis and advanced treatment options are expected to drive the adoption of biodegradable stents. In addition, several countries are implementing national healthcare strategies that prioritize minimally invasive treatments and promote research and development (R&D) in medical device innovation. The growing focus on value-based healthcare, which emphasizes the importance of cost-effective treatments that deliver better patient outcomes, is further supporting the expansion of the biodegradable stent market. As governments continue to prioritize healthcare advancements, the demand for biodegradable stents is likely to increase, contributing to the market’s overall growth trajectory.

Market Trends

Shift Towards Drug-Eluting Biodegradable Stents

One of the most significant trends in the global biodegradable stent market is the increasing shift toward drug-eluting biodegradable stents. Traditional bare-metal stents have been effective in providing mechanical support to blocked arteries; however, they are associated with high rates of restenosis. Drug-eluting stents (DES), on the other hand, release drugs that help reduce inflammation and prevent the growth of scar tissue, thus significantly lowering the risk of restenosis. Recent advancements in bioresorbable materials have allowed the development of drug-eluting biodegradable stents, which provide temporary mechanical support while releasing drugs to promote arterial healing. These stents are gaining preference among physicians and healthcare providers as they offer dual benefits: the mechanical support of a stent and the medicinal advantages of drug elution. Leading manufacturers are increasingly focusing on research and development (R&D) to enhance the efficacy and safety of these stents, making them a preferred choice in the treatment of coronary artery diseases. This trend is expected to drive innovation and propel the market further as healthcare providers seek to reduce long-term complications associated with traditional metallic stents. For instance, recent advancements in drug-eluting stents have shown promising results in reducing cardiovascular events.

Growing Adoption in Emerging Markets

Another noteworthy trend is the growing adoption of biodegradable stents in emerging markets, particularly in regions such as Asia-Pacific and Latin America. These regions are experiencing a rising incidence of cardiovascular diseases, driven by factors such as aging populations, changing lifestyles, and increasing urbanization. Additionally, healthcare infrastructure in these regions is improving, with governments and private sectors investing in advanced medical technologies to address the growing healthcare needs. Countries like India, China, and Brazil are witnessing a surge in demand for minimally invasive treatments, including biodegradable stents, as they offer a safer and more effective alternative to traditional stents. The growing awareness of the benefits of biodegradable stents, combined with the expansion of healthcare access in these regions, is fueling market growth. Moreover, manufacturers are exploring strategic partnerships and collaborations to tap into these high-growth markets, which are expected to be key drivers for the global biodegradable stent market in the coming years.

Market Restraints and Challenges

High Production Costs and Economic Barriers

One of the primary restraints facing the global biodegradable stent market is the high production costs associated with manufacturing these advanced medical devices. Biodegradable stents require sophisticated materials, such as polylactic acid (PLA) or magnesium-based alloys, and intricate manufacturing processes to ensure their bioresorbable properties and mechanical integrity. These factors contribute to higher prices compared to traditional metallic stents, potentially limiting their accessibility, especially in cost-sensitive markets. Additionally, the extensive research and development (R&D) investments needed to innovate and improve biodegradable stent technologies further escalate overall costs. Healthcare providers and patients may be hesitant to adopt these stents unless there is clear evidence of their long-term cost-effectiveness and superior clinical outcomes. Consequently, the high initial costs can act as a significant barrier to widespread adoption, particularly in emerging economies where healthcare budgets are constrained. For instance, recent surveys indicate that the high costs of biodegradable stents are a major concern for healthcare providers in emerging markets.

Regulatory Hurdles and Limited Long-Term Data

Another critical challenge for the biodegradable stent market is navigating the stringent regulatory landscape and addressing the limited long-term clinical data. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) impose rigorous standards for the approval of new medical devices, including biodegradable stents. Manufacturers must demonstrate not only the safety and efficacy of their products through extensive clinical trials but also provide comprehensive data on long-term outcomes and potential complications. The relative novelty of biodegradable stents compared to traditional stents means that there is still a paucity of long-term data, which can hinder regulatory approvals and delay market entry. Additionally, any adverse events or complications reported in post-market surveillance can impact the overall trust and acceptance of biodegradable stents among healthcare professionals and patients. Overcoming these regulatory challenges requires sustained investment in clinical research and robust post-market monitoring to build a strong evidence base that supports the benefits and safety of biodegradable stents. For instance, recent studies have highlighted the need for more long-term data to ensure the safety and efficacy of biodegradable stents.

Market Segmentation Analysis

By Stents

Coronary artery stents dominate the biodegradable stent market due to the high prevalence of coronary artery disease, as they are essential for keeping the coronary arteries open and ensuring adequate blood flow to the heart. Continuous advancements in bioresorbable materials have enhanced their efficacy and safety, making them the preferred choice for cardiac interventions. Concurrently, peripheral artery stents are gaining traction for treating peripheral artery disease (PAD), helping maintain arterial patency in limbs and thereby improving patient mobility and quality of life. The rising incidence of PAD, combined with technological improvements, is driving demand in this segment. Additionally, non-vascular biodegradable stents are being increasingly utilized in various surgical applications beyond the vascular system, including urology and gastroenterology. Although this segment remains smaller, it is experiencing steady growth due to expanding applications and the advantages of bioresorbable materials in reducing long-term complications.

By Application

The biodegradable stent market is primarily driven by its diverse applications across several medical fields. In the cardiovascular sector, biodegradable stents represent the largest segment, propelled by the global prevalence of heart diseases. These stents significantly reduce the risks of restenosis and thrombosis, making them ideal for cardiovascular interventions. In orthopaedics, biodegradable stents are utilized in spinal surgeries and fracture fixations, providing temporary support that gradually dissolves in harmony with the natural healing process, thereby minimizing the need for additional surgeries. Cosmetic surgery applications involve the use of these stents in facial reconstructive procedures, where they help maintain structural integrity during healing without leaving permanent implants. Additionally, in general surgery, biodegradable stents are employed in a wide range of procedures requiring temporary scaffolding, enhancing surgical outcomes by offering necessary support and then safely degrading within the body. Beyond these primary applications, the market is expanding into emerging areas such as gastroenterology and urology, where biodegradable stents are being explored for innovative treatment solutions. This broad spectrum of applications underscores the versatility and growing acceptance of biodegradable stents in enhancing patient care across multiple medical disciplines.

Segments

Based on Stents

• Coronary Artery Stents
• Peripheral Artery Stents
• Non-vascular Stents

Based on Application

• Cardiovascular
• Orthopaedics
• Cosmetic Surgery
• General Surgery
• Others

Based on End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centres (ASCs)

Based on Material

• Metallic
• Ceramic
• Polymers

Based on Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Regional Analysis

North America (40%)

North America dominates the biodegradable stent market, holding approximately 40% of the global share. This leadership is attributed to the region's advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and substantial investments in medical research and development. The United States, in particular, plays a pivotal role, supported by robust regulatory frameworks from the U.S. Food and Drug Administration (FDA) that facilitate the approval and adoption of innovative medical devices. Additionally, the presence of key market players and a strong emphasis on technological advancements further bolster North America's dominance. The increasing demand for minimally invasive procedures and the growing geriatric population are expected to sustain the region's leading position in the coming years.

Europe (30%)

Europe accounts for around 30% of the global biodegradable stent market. The region's market growth is driven by stringent regulatory standards set by the European Medicines Agency (EMA), which ensure the safety and efficacy of biodegradable stents. Countries such as Germany, the United Kingdom, and France are major contributors, supported by a strong focus on medical innovation and substantial healthcare expenditures. Europe's aging population and the rising incidence of cardiovascular diseases also enhance the demand for advanced stent technologies. Furthermore, collaborative research initiatives and the presence of leading biomedical companies in Europe facilitate continuous advancements in biodegradable stent development, reinforcing the region's significant market share.

Key players

• Boston Scientific Corporation
• Meril Life Sciences Pvt. Ltd.
• Medtronic Plc
• Smith & Nephew Plc
• Stryker Corporation
• Wright Medical Group
• KLS Martin
• BIOTRONIK Ltd
• Syntellix AG
• Q3 Medical Devices Limited
• JW Medical Systems Ltd
• OrbusNeich Medical
• Abbott Vascular

Competitive Analysis

The biodegradable stent market is highly competitive, characterized by the presence of both established multinational corporations and innovative emerging players. Boston Scientific Corporation and Medtronic Plc lead the market with their extensive research and development capabilities, offering a broad portfolio of advanced stent technologies. Abbott Vascular and BIOTRONIK Ltd also hold significant market positions, leveraging their strong brand reputation and robust distribution networks to capture substantial market share.  Emerging companies like Syntellix AG and OrbusNeich Medical are gaining traction through innovative bioresorbable materials and cutting-edge stent designs, addressing specific clinical needs and enhancing patient outcomes. Meril Life Sciences Pvt. Ltd. and Smith & Nephew Plc contribute to market diversity with their specialized product offerings and strategic partnerships. Additionally, smaller players such as Q3 Medical Devices Limited and JW Medical Systems Ltd are expanding their footprint by focusing on niche segments and regional markets. The competitive landscape is further intensified by continuous technological advancements, strategic mergers and acquisitions, and the pursuit of regulatory approvals, driving overall market growth and innovation.

Recent Developments

• On March 1, 2024, Boston Scientific received FDA approval for the AGENT™ Drug-Coated Balloon, which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.
• On May 13, 2022, Medtronic received FDA approval for the Onyx Frontier drug-eluting stent, which builds upon the acute performance and clinical data from the Resolute Onyx drug-eluting stent.
• On September 20, 2024, Stryker completed the acquisition of NICO Corporation, expanding its portfolio of minimally invasive solutions for brain tumor removal and stroke care.
• On March 27, 2024, KLS Martin reported another record year with significant growth and market share gains. The company continues to focus on its core product areas, including implant systems.
• On July 1, 2024, BIOTRONIK introduced expanded maximum diameter dimensions for the Orsiro Mission Drug-Eluting Stent (DES), reflecting a global effort to optimize vessel apposition.

Market Concentration and Characteristics 

The biodegradable stent market exhibits a moderately concentrated structure, dominated by a few key multinational corporations alongside a number of specialized and emerging players. Leading firms such as Boston Scientific Corporation, Medtronic Plc, and Abbott Vascular hold significant market shares due to their extensive research and development capabilities, robust distribution networks, and strong brand recognition. However, the market also features a dynamic landscape with innovative smaller companies like Syntellix AG and OrbusNeich Medical driving technological advancements and niche segment growth. This blend of established giants and agile innovators fosters a highly competitive environment characterized by continuous innovation, strategic partnerships, and frequent mergers and acquisitions. Additionally, the increasing emphasis on bioresorbable materials and advanced stent designs enhances market differentiation, while regulatory approvals and clinical validations remain critical factors influencing market entry and competitive positioning. Overall, the market’s concentration and diverse characteristics promote sustained growth and ongoing innovation within the biodegradable stent sector.

Report Coverage

The research report offers an in-depth analysis based on Stents, Application, End User, Material, Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

1. Advancements in bioresorbable materials and stent designs will enhance the performance and safety of biodegradable stents, fostering broader adoption in clinical settings.
2. Rapid economic growth and improving healthcare infrastructure in regions like Asia-Pacific and Latin America will significantly boost the demand for biodegradable stents.
3. Streamlined regulatory processes and increased approvals from agencies such as the FDA and EMA will facilitate faster market entry and expansion for biodegradable stent manufacturers.
4. Continuous investment in R&D by key players will lead to the development of next-generation biodegradable stents with improved bioresorption rates and drug-eluting capabilities.
5. The increasing incidence of cardiovascular conditions globally will drive the need for effective and minimally invasive treatment options, propelling the biodegradable stent market forward.
6. Collaborations between medical device companies, research institutions, and healthcare providers will accelerate innovation and expand the market reach of biodegradable stents.
7. The trend towards personalized medical treatments will encourage the development of customizable biodegradable stents tailored to individual patient needs, enhancing treatment outcomes.
8. Improvements in manufacturing processes and economies of scale will lower the production costs of biodegradable stents, making them more accessible to a wider patient population.
9. Beyond cardiovascular applications, biodegradable stents will find increased use in orthopaedics, cosmetic surgery, and general surgery, diversifying market opportunities and driving growth.
10. Growing awareness of environmental sustainability and the importance of biocompatible medical devices will further enhance the appeal and acceptance of biodegradable stents in the healthcare industry.

Rising Prevalence of Cardiovascular Diseases

The increasing global burden of cardiovascular diseases, such as coronary artery disease and stroke, is driving demand for effective and minimally invasive treatment options like biodegradable stents, which help restore blood flow and reduce long-term complications.

Technological Advancements in Stent Design and Materials

Continuous innovation in bioresorbable materials and drug-eluting technologies is enhancing the safety, efficacy, and adoption of biodegradable stents, making them more attractive compared to traditional metallic stents.

Increasing Preference for Minimally Invasive Procedures

Patients and healthcare providers are increasingly favoring minimally invasive interventions, and biodegradable stents align with this trend by offering temporary support and dissolving after healing, reducing the need for additional surgeries.

Government and Regulatory Support

Favorable regulatory approvals and reimbursement policies from agencies like the FDA and EMA are accelerating the adoption of biodegradable stents, while government investments in healthcare infrastructure further support market growth.

Growing Adoption in Emerging Markets

Rapid economic development and expanding healthcare access in Asia-Pacific and Latin America are increasing the uptake of advanced medical devices, including biodegradable stents, as awareness and demand for modern cardiovascular treatments rise.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.